Akebia Therapeutics (STU:AX9) Long-Term Debt : €27.7 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Long-Term Debt?

Akebia Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2024 was €27.7 Mil.

Akebia Therapeutics's quarterly Long-Term Debt declined from Sep. 2023 (€32.4 Mil) to Dec. 2023 (€15.8 Mil) but then increased from Dec. 2023 (€15.8 Mil) to Mar. 2024 (€27.7 Mil).

Akebia Therapeutics's annual Long-Term Debt increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€32.2 Mil) but then declined from Dec. 2022 (€32.2 Mil) to Dec. 2023 (€15.8 Mil).

Akebia Therapeutics Long-Term Debt Historical Data

The historical data trend for Akebia Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Long-Term Debt Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Long-Term Debt

Get a 7-Day Free Trial

68.23

79.22

32.17

15.76

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Long-Term Debt	Get a 7-Day Free Trial															24.56	17.06	32.43	15.76	27.73

Akebia Therapeutics (STU:AX9) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Akebia Therapeutics Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (STU:AX9) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (STU:AX9) » Definitions » Long-Term Debt

Comparable Companies

Traded in Other Exchanges

AKBA:USA AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Akebia Therapeutics (STU:AX9) Headlines

No Headlines